NASDAQ · MLTX
Healthcare · Biotechnology
$10.95
Down-$0.43 (-3.78%)
Updated Oct 7, 2026, 5:21 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MLTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MLTX closed at $10.95 after 21 trading sessions, down 26.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $11.50 | $11.50 | $10.91 | $10.95 | 3.05M |
| Oct 5, 2026 | $11.56 | $11.715 | $11.19 | $11.38 | 1.87M |
| Oct 2, 2026 | $11.64 | $11.65 | $11.03 | $11.41 | 1.83M |
| Oct 1, 2026 | $11.73 | $11.84 | $11.29 | $11.47 | 1.31M |
| Sep 30, 2026 | $11.52 | $12.00 | $11.385 | $11.70 | 1.99M |
| Sep 29, 2026 | $11.56 | $11.70 | $11.40 | $11.45 | 1.51M |
| Sep 28, 2026 | $12.04 | $12.04 | $11.53 | $11.56 | 1.66M |
| Sep 25, 2026 | $12.15 | $12.205 | $11.80 | $12.04 | 2.18M |
| Sep 24, 2026 | $12.69 | $12.83 | $12.04 | $12.12 | 1.9M |
| Sep 23, 2026 | $13.41 | $13.69 | $12.23 | $12.90 | 2M |
| Sep 22, 2026 | $12.73 | $13.44 | $12.54 | $13.38 | 2.36M |
| Sep 21, 2026 | $12.50 | $12.65 | $12.24 | $12.55 | 1.22M |
| Sep 18, 2026 | $12.28 | $12.4991 | $12.09 | $12.39 | 1.8M |
| Sep 17, 2026 | $12.66 | $12.80 | $12.20 | $12.35 | 2.3M |
| Sep 16, 2026 | $12.29 | $12.51 | $11.88 | $12.46 | 2.6M |
| Sep 15, 2026 | $12.70 | $12.70 | $12.02 | $12.20 | 1.8M |
| Sep 14, 2026 | $12.56 | $13.00 | $12.22 | $12.68 | 2.33M |
| Sep 11, 2026 | $13.33 | $13.55 | $12.4724 | $12.51 | 2.39M |
| Sep 10, 2026 | $13.58 | $13.62 | $13.12 | $13.18 | 1.22M |
| Sep 9, 2026 | $14.90 | $15.00 | $13.66 | $13.72 | 1.69M |
| Sep 8, 2026 | $14.80 | $15.43 | $14.69 | $14.94 | 1.46M |
The latest Smart Investors Daily articles mentioning MLTX.
Company
Market Activity
Research & News
MLTX research
Company profile and research snapshot.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 1, 2026 | Leerink Partners | Outperform | — |
| Jun 9, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
SeekingAlpha · Sep 8, 2026
MoonLake Immunotherapeutics (MLTX) investment outlook: sonelokimab durability, HS regulatory path, cash runway to 2028, and key risks.
Benzinga · Aug 13, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target from $45 to $50.
Yahoo · Aug 10, 2026
At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MLTX.
